Facebook Pixel APAC's 5G ambitions in Healthcare | BioSpectrum Asia - Business - Lees dit verhaal op Magzter.com
Ga onbeperkt met Magzter GOLD

Ga onbeperkt met Magzter GOLD

Krijg onbeperkte toegang tot meer dan 9000 tijdschriften, kranten en Premium-verhalen voor slechts

$149.99
 
$74.99/Jaar

Poging GOUD - Vrij

APAC's 5G ambitions in Healthcare

BioSpectrum Asia

|

November 2020

The surge in virtual healthcare has prompted physicians globally to engage in co-sharing their medical space and expertise. And Internet-of-Things (IoT) is driving next-generation smart healthcare. Boosted by advances in robotics, IoT and Artificial Intelligence, healthcare organisations across the globe have started using 5G network that promises to provide essential levels of connectivity to enable a new health ecosystem, which will align with a relatively recent idea known as 4P medicine—that is, it will be predictive, preventative, personalised and participatory, as noted by PwC.

- Hithaishi C Bhaskar

APAC's 5G ambitions in Healthcare

At present, most countries’ healthcare system widely uses the existing 4G (fourth generation of broadband cellular network technology) network and other communication technologies for smart healthcare applications. The existing communication technologies are unable to fulfil the complex and dynamic needs of the diverse smart healthcare applications, such as remote surgeries which imperatively require an ultrareliable network.

4G latency (lag time between input and output) is around 50 milliseconds, a delay long enough to prove devastating in an operating room. 5G (fifth generation mobile network) primarily aims to reduce latency to an almost instantaneous 2 milliseconds between devices. Hence a 5G network is essential to support smart healthcare infrastructure, through its ultra-low latency, high bandwidth, ultra-high reliability, high density and energy efficiency.

The ultra-reliable low-latency communications (URLLC) is advantageous for remote monitoring of pharma and medical devices, remote robotic surgeries, smart ambulance (logistics), and realtime augmented reality (AR)/ virtual reality (VR) applications. To list, 5G wireless technology, the Internet-of-Medical-Things (IoMT), artificial intelligence (AI), VR/AR tools and blockchain system are the five interconnected keys influencing digital healthcare. In summary, 5G transform current tedious manual processes into smartly automated workflows and provides integrated, enhanced patient care.

MEER VERHALEN VAN BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Alphamab Oncology appoints Fei Wang as Chief Financial Officer

Hong Kong-based Alphamab Oncology has announced the appointment of Fei Wang as the Chief Financial Officer (CFO).

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

CarbGeM inks MoU with DSS Imagetech to expand AI business in Indian market

DSS Imagetech, a leading player in medical and research imaging equipment, has announced the signing of a Memorandum of Understanding (MoU) with Japan-based CarbGeM Inc., a developer of artificial intelligence (AI)-powered life science solutions to expand its AI business in the Indian market.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

PHCbi introduces LiCellGrow Cell Expansion System

PHC Corporation's Biomedical Division, a global provider of laboratory sample storage and cell cultivation solutions and subsidiary of Japan's PHC Holdings Corporation, has announced the launch of its new cell expansion system LiCellGrow for research use in Japan and other select countries worldwide.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

CitiusTech appoints Dhaval Shah as Chief Business Officer - MedTech & Life Sciences

CitiusTech, a leading provider of healthcare technology services driving digital and AI excellence in India, has appointed Dhaval Shah to Chief Business Officer - MedTech & Life Sciences.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

Thermo Fisher expands immunodiagnostics operations with new distribution centre in Uppsala

Thermo Fisher Scientific Inc. has announced the opening of a new 8,000-square-meter distribution & labeling centre supporting its immunodiagnostics business in Uppsala.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Harbour BioMed appoints Dr Jenny Xie as Head of Global External Innovation

Harbour BioMed, a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, has announced the appointment of Dr Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Argo Biopharma ropes in Dr Gena Wang as CFO and CSO

China-based Argo Biopharmaceutical Co., a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, has announced the appointment of Dr Gena Wang as Chief Financial Officer (CFO) and Chief Strategy Officer (CSO), effective March 1, 2026.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

IISc launches "Moonshot" project on brain co-processors supported by Pratiksha Trust

The Indian Institute of Science (IISc), Bengaluru has launched an ambitious \"moonshot\" project to develop brain co-processors that combine neuromorphic hardware and artificial intelligence (AI) algorithms to enhance or restore brain function.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

Korea designs model for accurate and scalable drug-drug interaction prediction

A research team from the School of International Engineering and Science at Jeonbuk National University (JBNU), South Korea, has developed DDINet, a lightweight and scalable model, specifically designed to predict interactions for new, unseen drugs.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Australia-Singapore study advocates role of intranasal vaccine booster against sarbecoviruses

Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Monash University in Australia, have demonstrated that an intranasal vaccine booster may confer significantly stronger and broader immune responses, and provide robust neutralising antibody and resident T cell responses in the lung and nasal tissues, outperforming conventional mRNA booster vaccination.

time to read

1 min

BioSpectrum Asia April 2027

Translate

Share

-
+

Change font size